Development and evaluation of mucoadhesive nanoparticles based on thiolated Eudragit for oral delivery of protein drugs
Source abstract
Abstract
The objective of this study was to develop pH-sensitive Eudragit L100–cysteine/reduced glutathione (Eul–cys/GSH) nanoparticles (NPs), which provided the mucoadhesion and protection for protein drugs against enzymatic degradation. Insulin was chosen as a model biomolecule for testing this system. The Eul–cys conjugate, which was obtained by grafting cysteine onto the carboxy group of Eudragit L100, was analyzed by HNMR and SEM, and the swelling degree (SD), cation binding, and enzymatic inhibition were also determined. The results obtained showed that the Eul–cys conjugate represent a pH-sensitive delivery system which effectively protected the insulin from being degraded by the proteases, and this is related to the mechanism of Ca2+ binding. Insulin-loaded Eul–cys/GSH NPs were prepared by a diffusion method involving an electrostatic interaction between the network structure of the polymer and the embedded proteins, including insulin and GSH. TEM images indicated that Eul–cys/GSH existed as smooth and spherical NPs in aqueous solution with particle sizes of 260 ± 20 nm. The X-ray diffraction (XRD) and X-ray photoelectron spectroscopy (XPS) findings showed the presence of amorphous insulin in thiolated NPs and higher free thiol oxidation than the result obtained by Ellman’s reagent method. In addition, thiolated NPs showed excellent binding efficiency to the mucin in rat intestine, indicating that Eul–cys/GSH NPs have great potential to be applied as safe carriers for the oral administration of protein drugs.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Andreani T, Luiza A, Souto EB et al (2014) Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery. Int J Pharm 473:627–63510.1016/j.ijpharm.2014.07.049 ↗
2. Bakhru SH, Furtado S, Mathiowitz E et al (2013) Oral delivery of proteins by biodegradable nanoparticles. Adv Drug Deliv Rev 65:811–82110.1016/j.addr.2013.04.006 ↗
3. Bernkop-Schnürch A (2005) Mucoadhesive polymers: strategies, achievements and future challenges. Adv Drug Deliv Rev 57:1553–155510.1016/j.addr.2005.07.007 ↗
4. Bernkop-Schnürch A, Freudl A (1999) Comparative in vitro study of different chitosan-complexing agent conjugates. Pharmazie 54:369–371
5. Bernkop-Schnürch A, Krajicek ME (1998) Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates. J Controlled Release 50:215–22310.1016/S0168-3659(97)00136-3 ↗
6. Bernkop-Schnürch A, Zarti H, Walker GF (2001) Thiolation of polycarbophil enhances its inhibition of intestinal brush border membrane bound aminopeptidase N. J Pharm Sci 90:1907–191410.1002/jps.1140 ↗
7. Bravo-Osuna I, Millotti G, Vauthier C et al (2007) In vitro evaluation of calcium-binding capacity of chitosan and thiolated chitosan poly(isobutyl cyanoacrylate) core-shell nanoparticles. Int J Pharm 338:284–29010.1016/j.ijpharm.2007.01.039 ↗
8. Chickering DE, Mathiowitz E (1995) Bioadhesive microspheres: I. A novel electrobalance-based method to study adhesive interactions between individual microspheres and intestinal mucosa. J Controlled Release 34:251–26210.1016/0168-3659(95)00011-V ↗
9. Felber AE, Dufresne MH, Leroux JC (2012) pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv Drug Deliv Rev 64:979–99210.1016/j.addr.2011.09.006 ↗
10. Ganta S, Devalapally H, Amiji M et al (2008) A review of stimuli-responsive nanocarriers for drug and gene delivery. J Controlled Release 126:187–20410.1016/j.jconrel.2007.12.017 ↗
11. Herrero-Vanrell R, Rincón AC, Rodríguez-Cabello JC et al (2005) Self-assembled particles of an elastin-like polymer as vehicles for controlled drug release. J Controlled Release 102:113–12210.1016/j.jconrel.2004.10.001 ↗
12. Jin Y, Song Y, Huang Y et al (2012) Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33:1573–158210.1016/j.biomaterials.2011.10.075 ↗
13. Kim BG, Kang IJ (2008) Evaluation of the effects of biodegradable nanoparticles on a vaccine delivery system using AFM, SEM and TEM. Ultramicroscopy 108:1168–117310.1016/j.ultramic.2008.04.038 ↗
14. Luessen HL, Verhoef JC, Junginger HE et al (1995) Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm Res 12:1293–129810.1023/A:1016213405081 ↗
15. Luessen HL, de Leeuw BJ, Junginger HE et al (1996) Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res 13:1668–167210.1023/A:1016488623022 ↗
16. Mao S, Bakowsky U, Kissel T et al (2006) Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulin. J Pharm Sci 95:1035–104810.1002/jps.20520 ↗
17. Mukhopadhyay P, Sarkar K, Kundu PP et al (2013) Oral insulin delivery by self-assembled chitosan nanoparticles: in vitro and in vivo studies in diabetic animal model. Mater Sci Eng C 33:376–38210.1016/j.msec.2012.09.001 ↗
18. Pawar H, Douroumis D, Boateng JS (2012) Preparation and optimization of PMAA-chitosan-PEG nanoparticles for oral drug delivery. Colloids Surf B 90:102–10810.1016/j.colsurfb.2011.10.005 ↗
19. Ponchel G, Irache JM (1998) Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev 34:191–21910.1016/S0169-409X(98)00040-4 ↗
20. Schmitz T, Grabovac V, Bernkop-Schnürch A et al (2008) Synthesis and characterization of a chitosan-N-acetyl cysteine conjugate. Int J Pharm 347:79–8510.1016/j.ijpharm.2007.06.040 ↗
21. Su FY, Lin KJ, Sung HW et al (2012) Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 33:2801–281110.1016/j.biomaterials.2011.12.038 ↗
22. Tiyaboonchai W, Woiszwillo J, Middaugh CR et al (2003) Insulin containing polyethylenimine-dextran sulfate nanoparticles. Int J Pharm 255:139–15110.1016/S0378-5173(03)00055-3 ↗
23. Torchilin V (2008) Intracellular delivery of protein and peptide therapeutics. Drug Discov Today 5:e95–e10310.1016/j.ddtec.2009.01.002 ↗
24. Vauthier C, Dubernet C, Couvreur P et al (2003) Drug delivery to resistant tumors: the potential of poly (alkyl cyanoacrylate) nanoparticles. J Controlled Release 93:151–16010.1016/j.jconrel.2003.08.005 ↗
25. Wee S, Gombotz WR (1998) Protein release from alginate matrices. Adv Drug Deliv Rev 31:267–28510.1016/S0169-409X(97)00124-5 ↗
26. Yamagata T, Morishita M, Peppas NA et al (2006) Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fluids. J Controlled Release 112:343–34910.1016/j.jconrel.2006.03.005 ↗
27. Yin L, Ding J, Yin C et al (2010) Polymer integrity related absorption mechanism of superporous hydrogel containing interpenetrating polymer networks for oral delivery of insulin. Biomaterials 31:3347–335610.1016/j.biomaterials.2010.01.045 ↗
28. Zhang Y, Wu X, Tang X et al (2012) Thiolated Eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation. Int J Pharm 436:341–35010.1016/j.ijpharm.2012.06.054 ↗
29. Zhang Y, Du X, Tang X et al (2014) Thiolated Eudragit based nanoparticles for oral insulin delivery: preparation, characterization, and evaluation using intestinal epithelial cells in vitro. Macromol Biosci 14:842–85210.1002/mabi.201300515 ↗